OBJECTIVE: Gastric colonisation with the Helicobacter pylori bacterium is a proposed protective factor against oesophageal adenocarcinoma, but its point of action is unknown. Its associations with Barrett's oesophagus, a metaplastic change that is a probable early event in the carcinogenesis of oesophageal adenocarcinoma, were evaluated METHODS: A case-control study was carried out in the Kaiser Permanente Northern California population, a large health services delivery organisation. Persons with a new Barrett's oesophagus diagnosis (cases) were matched to subjects with gastro-oesophageal reflux disease (GORD) without Barrett's oesophagus and to population controls. Subjects completed direct in-person interviews and antibody testing for H pylori and its CagA (cytotoxin-associated gene product A) protein. RESULTS: Serological data were available on 318 Barrett's oesophagus cases, 312 GORD patients and 299 population controls. Patients with Barrett's oesophagus were substantially less likely to have antibodies for H pylori (OR = 0.42, 95% CI 0.26 to 0.70) than population controls; this inverse association was stronger among those with lower body mass indexes (BMIs < 25, OR = 0.03, 95% CI 0.00 to 0.20) and those with CagA+ strains (OR = 0.08, 95% CI 0.02 to 0.35). The associations were diminished after adjustment for GORD symptoms. The H pylori status was not an independent risk factor for Barrett's oesophagus compared with the GORD controls. CONCLUSIONS: Helicobacter pylori infection and CagA+ status were inversely associated with a new diagnosis of Barrett's oesophagus. The findings are consistent with the hypothesis that H pylori colonisation protects against Barrett's oesophagus and that the association may be at least partially mediated through GORD.
OBJECTIVE: Gastric colonisation with the Helicobacter pylori bacterium is a proposed protective factor against oesophageal adenocarcinoma, but its point of action is unknown. Its associations with Barrett's oesophagus, a metaplastic change that is a probable early event in the carcinogenesis of oesophageal adenocarcinoma, were evaluated METHODS: A case-control study was carried out in the Kaiser Permanente Northern California population, a large health services delivery organisation. Persons with a new Barrett's oesophagus diagnosis (cases) were matched to subjects with gastro-oesophageal reflux disease (GORD) without Barrett's oesophagus and to population controls. Subjects completed direct in-person interviews and antibody testing for H pylori and its CagA (cytotoxin-associated gene product A) protein. RESULTS: Serological data were available on 318 Barrett's oesophagus cases, 312 GORD patients and 299 population controls. Patients with Barrett's oesophagus were substantially less likely to have antibodies for H pylori (OR = 0.42, 95% CI 0.26 to 0.70) than population controls; this inverse association was stronger among those with lower body mass indexes (BMIs < 25, OR = 0.03, 95% CI 0.00 to 0.20) and those with CagA+ strains (OR = 0.08, 95% CI 0.02 to 0.35). The associations were diminished after adjustment for GORD symptoms. The H pylori status was not an independent risk factor for Barrett's oesophagus compared with the GORD controls. CONCLUSIONS:Helicobacter pyloriinfection and CagA+ status were inversely associated with a new diagnosis of Barrett's oesophagus. The findings are consistent with the hypothesis that H pylori colonisation protects against Barrett's oesophagus and that the association may be at least partially mediated through GORD.
Authors: F Cremonini; S Di Caro; S Delgado-Aros; A Sepulveda; G Gasbarrini; A Gasbarrini; M Camilleri Journal: Aliment Pharmacol Ther Date: 2004-01-01 Impact factor: 8.171
Authors: J C Wu; J J Sung; F K Chan; J Y Ching; A C Ng; M Y Go; S K Wong; E K Ng; S C Chung Journal: Aliment Pharmacol Ther Date: 2000-04 Impact factor: 8.171
Authors: Douglas K Rex; Oscar W Cummings; Michael Shaw; Mark D Cumings; Roy K H Wong; Raj S Vasudeva; Donal Dunne; Emad Y Rahmani; Debra J Helper Journal: Gastroenterology Date: 2003-12 Impact factor: 22.682
Authors: Arto Kokkola; Timo U Kosunen; Pauli Puolakkainen; Pentti Sipponen; Matti Harkonen; Frank Laxen; Jarmo Virtamo; Reijo Haapiainen; Hilpi Rautelin Journal: APMIS Date: 2003-06 Impact factor: 3.205
Authors: F Cremonini; S Di Caro; S Delgado-Aros; A Sepulveda; G Gasbarrini; A Gasbarrini; M Camilleri Journal: Aliment Pharmacol Ther Date: 2003-08-01 Impact factor: 8.171
Authors: Anna H Wu; Jean E Crabtree; Leslie Bernstein; Peter Hawtin; Myles Cockburn; Chiu-chen Tseng; David Forman Journal: Int J Cancer Date: 2003-03-01 Impact factor: 7.396
Authors: Aaron P Thrift; Nirmala Pandeya; Kylie J Smith; Adèle C Green; Nicholas K Hayward; Penelope M Webb; David C Whiteman Journal: Int J Cancer Date: 2011-08-17 Impact factor: 7.396
Authors: Stuart J Thomas; Lucy Almers; Jennifer Schneider; James E Graham; Peter J Havel; Douglas A Corley Journal: Dig Dis Sci Date: 2015-09-22 Impact factor: 3.199
Authors: Sabine Kienesberger; Laura M Cox; Alexandra Livanos; Xue-Song Zhang; Jennifer Chung; Guillermo I Perez-Perez; Gregor Gorkiewicz; Ellen L Zechner; Martin J Blaser Journal: Cell Rep Date: 2016-02-04 Impact factor: 9.423
Authors: Roberto Herrera-Goepfert; Luis F Oñate-Ocaña; José Luis Mosqueda-Vargas; Luis A Herrera; Clementina Castro; Julia Mendoza; Rodrigo González-Barrios Journal: World J Gastroenterol Date: 2016-05-14 Impact factor: 5.742